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The BRG-1 subunit of the SWISNF complex is in-
volved in chromatin remodeling and has been impli-
cated in the action of the retinoblastoma tumor suppres-
sor (RB). Given the importance of BRG-1 in RB function,
germ line BRG-1 mutations in tumorigenesis may be
tantamount to RB inactivation. Therefore, in this study
we assessed the behavior of cells harboring discrete
BRG-1 alleles for the RB-signaling pathway. Using
p16ink4a, an upstream activator of endogenous RB, or a
constitutively active RB construct (PSM-RB), we deter-
mined that the majority of tumor lines with germ line
defects in BRG-1 were sensitive to RB-mediated cell cy-
cle arrest. By contrast, A427 (lung carcinoma) cells were
resistant to expression of p16ink4a and PSM-RB. Analy-
sis of the SWISNF subunits in the different tumor lines
revealed that A427 are deficient for BRG-1 and its ho-
mologue, Brm, whereas RB-sensitive cell lines retained
Brm expression. Similarly, the RB-resistant SW13 and
C33A cell lines were also deficient for both BRG-1/Brm.
Reintroduction of either BRG-1 or Brm into A427 or
C33A cells restored RB-mediated signaling to cyclin A to
cause cell cycle arrest. Consistent with this compensa-
tory role, we observed that Brm could also drive expres-
sion of CD44. We also determined that loss of these core
SWISNF subunits renders SW13 cells resistant to acti-
vation of the RB pathway by the chemotherapeutic
agent cisplatin, since reintroduction of either BRG-1 or
Brm into SW13 cells restored the cisplatin DNA-damage
checkpoint. Together, these data demonstrate that Brm
can compensate for BRG-1 loss as pertains to RB
sensitivity.
The SWISNF complex consists of 10–12 proteins that form
an 2-MDa complex. This multisubunit complex regulates
transcription through its ability to remodel chromatin (1–3).
Specifically, the SWISNF complex has been shown to alter
nucleosome structure by disrupting histone-DNA interactions
in an ATP-dependent manner (4, 5). The precise mechanism
through which SWISNF regulates gene promoters in mam-
mals is unresolved. However, gene regulation studies in Sac-
charomyces cerevisiae demonstrate that SWISNF complexes
can localize to specific gene promoters, disrupting nucleosomal
DNA to modulate transcription (6–9). Specifically, it has been
shown that ISW2, a member of the ISWI class of chromatin
remodelers, is recruited to the promoter of meiotic genes by
Ume6p (a sequence-specific DNA-binding protein) to repress
transcription (6). In addition, it has been shown that the
SWISNF-related complex RSC (remodels the structure of chro-
matin) is targeted to the CHA1 promoter to maintain the nu-
cleosomal DNA in a repressed state (8). The mammalian
SWISNF complex contains either BRG-1 or Brm as its central
subunit. In addition, the complex is composed of accessory
proteins termed BRG-1-associated factors (Bafs)1 (10). Both
BRG-1 and Brm harbor the ATPase activity required for the
complex to function in remodeling (11). BRG-1 has been dem-
onstrated to regulate the transcription of a host of genes in-
volved in disparate cellular processes. For example, BRG-1 has
been shown to be required for the basal expression of the
membrane glycoprotein, CD44 (12). In addition, BRG-1 has
been shown to modulate estrogen receptor, glucocorticoid re-
ceptor, c-Myc, BRCA1, and retinoblastoma tumor suppressor
protein (RB) transcriptional activity (13–18). Because BRG-1 is
involved in regulating the transcription of such a diverse array
of genes as well as cooperating with both tumor suppressors
and oncogenes, it is a likely candidate for mutation in cancer.
Interestingly, it was recently reported that BRG-1 is mutated
or deleted in 10% of tumor cell lines analyzed, bolstering its
putative role as a prototypical tumor suppressor (19).
SWISNF activity was first linked to RB by the finding that
BRG-1 can bind to and cooperate with RB for arrest (20, 21).
The retinoblastoma tumor suppressor protein exhibits anti-
tumor activity by regulating the mitotic cell cycle (22–28). RB
was initially identified based on bi-allelic loss in retinoblas-
toma, a rare pediatric eye cancer (22, 23, 27, 28). Further
studies revealed that RB is also functionally inactivated in a
variety of human tumors via the following mechanisms, which
are (i) oncoprotein binding of DNA tumor viruses (e.g. E7 and
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human papilloma virus (HPV)), (ii) deregulated phosphoryla-
tion/inactivation by kinases that specifically phosphorylate RB,
and by (iii) mutation of the endogenous RB gene itself (22, 23,
26–29). Although these lesions directly target RB, it was re-
cently demonstrated that RB cell cycle inhibitory activity is
also compromised because of the loss of BRG-1, providing evi-
dence for an additional mechanism utilized by tumor cells to
disrupt RB signaling (17, 18, 30). Therefore, in the discrete
BRG-1 mutant tumor lines identified by Wong et al. (19), al-
teration of endogenous BRG-1 alleles were hypothesized to
compromise RB-mediated cell cycle control, providing the first
link between germ line mutations of BRG-1 and resistance to
the RB pathway (19).
RB regulates the cell cycle by assembling a multi-protein
complex that actively represses the transcription of genes re-
sponsible for driving DNA synthesis (24, 26, 31, 32). The E2F
family of transcription factors, which regulates the expression
of genes that drive entry into S-phase, are thought to be the
major target of RB (24). In addition, recruitment of histone
deacetylases facilitates RB-mediated repression of E2F tran-
scriptional activity (33, 34). Recently it was shown that BRG-1
is also a component of the RB repressor complex, and is re-
quired for RB-mediated inhibition of cyclin A expression, a
critical component of the Cdk2 kinase complex (17, 18, 30). This
regulation is significant as cyclin A/Cdk2 expression is re-
quired for cell cycle progression (35, 36).
In this study we analyzed whether tumor cell lines harboring
discrete BRG-1 mutations are compromised for RB responsive-
ness. Of the tumor lines analyzed, only the A427 lung carci-
noma cell line was resistant to both p16ink4a and an active
phosphorylation site mutant of RB (PSM-RB). We have previ-
ously identified C33A and SW13 as lacking in RB function due
to the loss of BRG-1 activity (17, 18, 30). Surprisingly, we
observed that loss of both BRG-1 and Brm was correlative with
RB insensitivity and a lack of CD44 expression in A427, C33A,
and SW13 cells. Co-expression of either BRG-1 or Brm with
PSM-RB specifically restored RB-mediated cell cycle inhibition
in A427 and C33A cells as well as CD44 levels in SW13, C33A,
and A427. Using the chemotherapeutic agent cisplatin (CDDP),
which has previously been shown to activate RB to inhibit
entry into S-phase (37, 38), we show that loss of BRG-1 and
Brm also mediates sensitivity to this specific DNA-damage
pathway. Thus, this report provides genetic and functional
evidence that Brm can substitute for BRG-1 in the regulation of
RB tumor suppressor activity.
MATERIALS AND METHODS
Cells, Plasmids, and Transfection—SW13, TSU-Pr-1, Hs578t,
Hs683, and HCT-116 cells were maintained in Dulbecco’s modified
Eagle’s medium, A427, WiDr, NCI-H1299, and SU86.86 cells were
maintained in RPMI. Both Dulbecco’s modified Eagle’s medium and
RPMI were supplemented with 10% heat-inactivated fetal bovine se-
rum, 100 units/ml penicillin-streptomycin, and 2 mM L-glutamine at
37 °C in 5% CO2. Plasmids were transfected using either calcium phos-
phate or the lipid-based transfection reagent FuGENE (Roche Molecu-
lar Biochemicals) (39). The plasmids CMV-NEO, pBabe-Puro, PSM-RB,
Brm, and BRG-1 have been previously described (20, 40–42). All of the
cell lines except TSU-Pr1 were obtained from ATCC. TSU-Pr1 was
obtained from J. Isaacs (Johns Hopkins).
Adenoviral Infections—For adenoviral infections 2  105 cells were
seeded on coverslips in six-well dishes. The green fluorescent protein
(GFP) adenovirus was provided by Dr. Gustavo Leone (Ohio State
University), and the p16ink4a adenovirus was supplied by Dr. Timothy
Kowalik (University of Massachusetts) and prepared as previously de-
scribed (43). The infections were performed at a calculated multiplicity
of infection of 50–100 for 95–100% infection efficiency after 16 h, as
judged by GFP expression.
Immunoblotting—Approximately 1  106 A427, C33A, or SW13 cells
were plated in 10-cm dishes 24 h before transfection. A427, C33A, and
SW13 cells were co-transfected with effectors and the puromycin-select-
able plasmid (pBabe-Puro). Transfected A427, C33A, and SW13 cells
were subsequently selected with 1.0, 2.5, or 2.5 g/ml puromycin (Sig-
ma), respectively, for 24–48 h and then harvested for immunoblot
analysis. Before CDDP treatment or adenovirus infection, 2  105
cells were seeded into each well of a 6-well dish. After 24 h of CDDP
treatment or infection, the cells were harvested. To isolate protein for
Western blotting, cells were trypsinized and subsequently washed with
PBS. The cell pellets were resuspended in radioimmune precipitation
buffer supplemented with protease inhibitor mixture (10 mg/ml, 1,10
phenanthroline, 10 mg/ml aprotinin, 10 mg/ml leupeptin, and 1 mM
phenylmethylsulfonyl fluoride) and incubated for 15 min on ice. The
lysates were briefly sonicated and then centrifuged for 10 min at
20,000  g at 4 °C. To isolate BRG-1 or Brm, total protein was isolated
from sub-confluent cultures using an 8 M urea extraction (8 M urea, 0.1
M NaH2PO4, 10 mM Tris, pH 8). The lysates were then separated via
SDS-polyacrylamide gel electrophoresis and then transferred onto Im-
mobilon-P (Millipore). Membranes were then incubated with either of
the following antibodies: anti-CD44 (Hermes 3), anti-Cdk4 (clone H22,
Santa Cruz), anti-cyclin E (clone C19 Santa Cruz), anti-cyclin A (clone
H432, Santa Cruz), anti--tubulin (Sigma), anti-p53 (Dr. K. Fukasawa,
University of Cincinnati, College of Medicine, Cincinnati, OH), anti-
pRB (Dr. J. Wang, University of California San Diego, 851 polyclonal
antibody), anti-phospho-RB (Ser-780) and anti-BRG-1 or anti-Brm (Dr.
Weidong Wang, National Institute of Health, Baltimore, MD; Dr.
Moshe Yaniv, Pasteur Institute). The blots were then incubated with
either horseradish peroxidase-conjugated anti-rabbit or anti-mouse an-
ti-sera for 1 h at room temperature. The antibody-antigen complex was
detected by enhanced chemiluminescence (ECL, Amersham Bio-
sciences, Inc.). The levels of -tubulin and cyclin A were quantitated
using Metamorph software (Universal Imaging Corporation).
Bromodeoxyuridine (BrdUrd) Incorporation—Approximately 2  105
cells were seeded onto coverslips in each well of a 6-well dish. Twenty-
four hours later the cells were either transfected or infected with ade-
novirus and then treated with CDDP. Forty-eight hours post-transfec-
tion, 24 h post-infection, or 24 h post-CDDP treatment the cells were
labeled with BrdUrd to detect DNA synthesis. After 16 h of labeling, the
cells were fixed in 3.7% formaldehyde and processed to detect BrdUrd
via indirect immunofluorescence as previously described (30).
RESULTS
Genetic analysis performed by Wong et al. (19) demonstrated
that BRG-1 is deleted or mutated in 10% of the tumor cell
lines examined. Several types of mutations were reported, as
summarized in Table I. For example, it was determined that
the COOH-terminal region of BRG-1 is homozygously deleted
in the prostate carcinoma cell line TSU-Pr1 and the A427 lung
carcinoma cell line. In addition, the tumor lines NCI-H1299
(lung), Hs 700t (pancreatic), Hs 578t (breast) and the HCT-116
(colorectal) cell line contained hemizygous mutations that re-
sulted in either a point mutation, frameshift, or a truncated
product (19). Last, heterozygous mutations were also observed
in the SU86.86 (pancreatic), WiDr (colorectal), and the Hs 683
(brain) tumor cell lines. We have previously shown that BRG-1
is required for RB activity and predicted that some of these
TABLE I
Disparate mutant BRG-1 alleles
As reported by Wong et al. (19), the following BRG-1 mutations were
discovered using radiation hybrid mapping and PCR sequence-based
mutation screens as previously described.
Tumor
cell line Tissue Genotype Mutation
TSU-Pr1 Prostate Hemizygous Deletion/truncated
A-427 Lung Hemizygous Deletion/truncated
NCI-H1299 Lung Hemizygous 69-Base deletion
Hs 700t Pancreas Hemizygous 729C/frameshift
Hs 578t Breast Hemizygous C589T/Pro 3 Ser
HCT-116 Colon Hemizygous T348C/Leu 3 Pro
SW13 Adrenal
C33A Cervix
SU86.86 Pancreas Heterozygous A479G/Gln 3 Arg
WiDr Colon Heterozygous G3850A/Asp 3 Asn
Hs 683 Brain Heterozygous T4826C/Leu 3 Pro
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BRG-1-derived tumor alleles may confer resistance to the anti-
proliferative activity of RB.
Analysis of p16ink4a Signaling in Discrete Mutant BRG-1
Tumor Cell Lines—To test this hypothesis, p16ink4a was first
employed. Numerous studies show that p16ink4a inhibits cell
cycle progression by inactivating the cyclin D-Cdk4 kinase
complex, ultimately resulting in the dephosphorylation/activa-
tion of RB (44, 45). Because BRG-1 is required for RB to
mediate cell cycle arrest in response to p16ink4a, we examined
whether this RB signaling pathway is intact in the disparate
BRG-1 mutant tumor lines (17). Each indicated BRG-1 mutant
line was infected with adenovirus encoding either GFP or
p16ink4a and subsequently monitored for their ability to incor-
porate BrdUrd (43). As shown in Fig. 1, several BRG-1 mutant
cell lines were inhibited for BrdUrd incorporation in response
to p16ink4a infection. TSUPr1 demonstrated an 50% reduc-
tion in BrdUrd incorporation as compared with GFP infection.
Likewise, NCI-H1299, Hs 578t, SU86.86, and Hs 683 demon-
strated a 40, 68, 52, and 60% decrease in BrdUrd, respectively
(Fig. 1.). These results indicate that the p16ink4a/RB axis is
intact in these cells. By contrast, A427 and HCT-116 were
relatively resistant to p16ink4a infection, showing only a 0 and
6.4% reduction in BrdUrd incorporation, respectively. Hs 700t
and WiDr demonstrated intermediate effects, showing only a
34 and 25% reduction in BrdUrd incorporation, respectively.
These results provided the impetus to further study the BRG-
1-RB link in A427, Hs 700t, WiDr, and HCT-116 cells.
Active/Dephosphorylated RB Is Defective in Signaling to
Critical Cell Cycle Targets in the A427 Cell Line—The role of
BRG-1 in transducing RB inhibitory signals has been shown to
be due to its ability to facilitate RB-mediated repression of
cyclin A (18, 30). To determine whether activation of RB in
either the p16ink4a-resistant cell lines A427, Hs 700t, and
HCT-116 or p16ink4a-sensitive cell lines TSU-Pr1 and NCI-
H1299 can signal to endogenous Cdk/cyclins, we utilized either
GFP- or p16ink4a-encoding recombinant adenoviruses. In
p16ink4a-sensitive cells (TSU-Pr1 and NCI-H1299), p16ink4a
introduction resulted in RB dephosphorylation/activation con-
comitant with a decrease in cyclin A levels by 98 and 92%,
respectively. p16ink4a expression in TSU-Pr1 and NCI-H1299
had no significant effect on cyclin E or Cdk2 protein levels after
comparison to GFP-infected cells and normalized to -tubulin
(Fig. 2A, lanes 3 and 4 and lanes 5 and 6). In Hs 700t cells,
overexpression of p16ink4a was inconsequential, as no detect-
able RB protein was observed (Fig. 2A, lanes 1 and 2). In
HCT-116 cells, p16ink4a expression resulted in only minimal
RB dephosphorylation (Fig. 2A, lanes 7 and 8). As would be
expected based on these results, RB activity was also lacking,
as evidenced by the retention of cyclin A protein (Fig. 2A, lanes
7 and 8). These data support the hypothesis that RB is largely
refractory to the effects of p16ink4a in HCT-116 cells. Similar
results were observed in WiDr cells (data not shown). Thus, the
inability of p16ink4a to completely activate RB in HCT-116 and
WiDr provides an explanation as to why these cell lines were
not arrested by p16ink4a. Interestingly, ectopic expression of
p16ink4a in A427 cells resulted in the efficient dephosphoryl-
ation of RB; however, activation of RB in this cell line was
defective in attenuating cyclin A levels when compared with
GFP-infected cells (Fig. 2A, lanes 9 versus 10). To confirm that
p16ink4a was efficiently dephosphorylating RB in A427 cells,
immunoblots were performed using a phospho-RB-specific an-
tibody (Ser-780). This antibody has been previously docu-
mented to detect only the phosphorylated form of RB (46).
Using HCT-116 as a positive control, we observed as expected
that ectopic expression of p16ink4a does not efficiently dephos-
phorylate RB (Fig. 2B, lanes 1 versus 2). Therefore, with the
Ser-780 antibody, we detected phosphorylated RB in both the
GFP- and p16ink4a-infected lanes (Fig. 2B, lanes 1 versus 2).
Next we probed A427 cells and determined that the Ser-780
antibody was able to detect the phosphorylated form of RB in
the GFP-infected cells. However, we were unable to detect
phosphorylated RB in A427 cells infected with p16ink4a (Fig.
2B, lanes 3 versus 4). Thus, these data indicate that of the lines
tested, RB signaling to critical downstream effectors is abro-
gated specifically in the A427 cell line.
The A427 Tumor Line Is Resistant to an Active Form of
RB—Because p16ink4a failed to activate endogenous RB in
WiDr and HCT-116 cells and since endogenous active RB
failed to signal in A427 cells, we tested the effect of activated
RB on cell cycle progression in these cells. For these experi-
ments we used a constitutively active allele of RB, PSM-RB,
which cannot be phosphorylated/inactivated. Specifically,
PSM-RB was co-transfected with an H2B-GFP expression
construct, and the ability of the transfected cells (GFP-posi-
tive) to incorporate BrdUrd was monitored. As expected, ec-
topic expression of PSM-RB in Hs 683 resulted in a 57%
decrease in BrdUrd incorporation when compared with vec-
tor-transfected cells (Fig. 3). Interestingly, overexpression of
PSM-RB in HCT-116, Hs 700t, and WiDr was sufficient to
inhibit cell cycle progression by 70, 65, and 83%, respec-
FIG. 1. Analysis of p16ink4a signaling in mutant BRG-1 tumor
lines. TSU-Pr1, A427, NCI-H1299, Hs 700t, Hs 578t, HCT-116,
SU86.86, SW13, Hs 683, and WiDr were infected with adenoviruses
harboring either GFP (vector) or p16ink4a. The GFP encoding adeno-
viruses infected 95–100% of the cells. The percentage of BrdUrd-
positive cells was determined from at least two independent experi-
ments with at least 150 infected cells scored per experiment.
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tively, when compared with vector (Fig. 3). These results
indicate that although p16ink4a does not initiate RB-medi-
ated cell cycle arrest, the RB pathway is still intact. By
contrast, in A427 cells, the percent of PSM-RB-transfected
cells incorporating BrdUrd was similar to that of vector
transfected cells (Fig. 3). Because A427 cells are resistant to
cell cycle arrest initiated by both ectopic RB and by activation
of endogenous RB, these results indicate that the BRG-1-RB
axis is specifically compromised in this cell line.
Loss of Both BRG-1 and Brm Expression Correlates with RB
Resistance—The mutant BRG-1 alleles present in several RB/
p16ink4a-responsive lines were reported to result in a lack of
detectable BRG-1 protein (19). Because we have previously
shown that BRG-1 function is required for an RB-mediated cell
cycle arrest, it was therefore surprising that so many cell lines
arrested in response to RB. One possible explanation could be
that Brm was still expressed in the disparate tumor lines.
Therefore, we initially probed the status of Brm as well as the
Bafs, Baf 250, Baf 180, Baf 155, Baf 57, and Baf 53, in the
various mutant BRG-1 tumor lines. Immunoblot analysis re-
vealed that the RB-sensitive SU86.86, HCT-116, Hs 683, WiDr,
and Hs 578t cell lines express BRG-1 and Brm as well as the
accessory SWISNF subunits Baf 250, Baf 180, Baf 155, Baf 57,
and Baf 53 after comparison to the HeLa-positive control (Fig.
4A, lanes 1, 4, 5, 7, 9, and 12) (19). Interestingly, the RB-
sensitive Hs 700t, TSU-PR1, and NCI-H1299 cell lines had low
levels of BRG-1 (19), comparable with that observed in C33A,
but Brm was still detectable, suggesting that in these cell lines
Brm may compensate for BRG-1 in mediating RB action (Fig.
4A, lanes 3, 6, 8, and 11). In the Hs 700t, TSU-PR1, and
NCI-H1299 cell lines, the expression of Baf 250, Baf 180, Baf
155, Baf 57, and Baf 53 proteins was also detected(Fig. 4A,
lanes 6, 8, and 11). Analysis of the RB-resistant A427 cell line
revealed the absence of both BRG-1 and Brm protein (Fig. 4A,
lane 10). The loss of both BRG-1 and Brm observed in the A427
cell line was similar to that found in the RB-resistant C33A and
SW13 cell lines (Fig. 4A, lanes 2, 3, and 10). Therefore, these
data suggest that loss of both BRG-1 and Brm may be a general
mechanism through which cells bypass RB inhibitory signals
and that Brm may compensate for BRG-1 in tumor cells.
We have previously shown that BRG-1 regulates the expres-
sion of CD44 (12). Therefore, we wanted to determine whether
these BRG-1 mutant tumor lines were compromised for this
signaling pathway. Immunoblot analysis revealed that the
BRG-1/Brm-positive SU86.86, HCT-116, Hs 683, WiDr, and Hs
578t cell lines express CD44 when compared with HeLa cells
(Fig. 4B, lanes 1, 4, 5, 7, 9, and 12). The Hs 700t, TSU-PR1, and
NCI-H1299 cell lines, which express Brm and limiting amounts
of BRG-1, were positive for CD44 (Fig. 4B, lanes 6, 8, and 11),
suggesting that Brm may also compensate for the lack of
BRG-1. However, A427 cells, like SW13 and C33A, were neg-
ative for CD44 expression, consistent with the notion that
BRG-1 and Brm function are compromised in this cell line (Fig.
4B, lanes 2, 3, and 10). Thus, CD44 loss is correlative with
disruption of SWISNF activity and could potentially be used as
a marker for RB resistance.
Restoration of Core SWISNF Subunits Restores RB Inhibi-
tory Activity—Because these data suggest that Brm can com-
pensate for BRG-1 mutation or loss, we investigated whether
reintroduction of Brm could restore RB signaling in C33A and
A427 cells. To test this idea, A427 and C33A cells were co-
transfected with H2B-GFP and either vector, BRG-1, Brm,
PSM-RB, BRG-1  PSM-RB, or Brm  PSM-RB and monitored
for BrdUrd incorporation. A427 and C33A cells transfected
with vector, BRG-1, and PSM-RB alone incorporated BrdUrd at
approximately equal rates (Fig. 5A, left and right panels). In-
terestingly, co-transfection of PSM-RB  BRG-1 or PSM-RB 
Brm caused a decrease in BrdUrd incorporation by 63 and
62%, respectively, in A427 cells and by 70 and 68% in C33A
cells (Fig. 5A, left and right panels). We have previously shown
FIG. 2. In A427 cells active/hy-
pophosphorylated RB is abrogated in
signaling to cyclin A. A, Hs 700t, TSU-
Pr1, NCI-H1299, HCT-116, and A427
cells were treated with either GFP or
p16ink4a adenoviruses. After incubating
for 24 h, equal total protein was resolved
by SDS-PAGE and then immunoblotted
for cyclin A, cyclin E, Cdk2, -tubulin,
pRB, and p16ink4a. B, HCT-116 and
A427 cells were infected with either GFP
or p16ink4a adenoviruses. After incubat-
ing for 24 h, equal total protein was re-
solved by SDS-PAGE and then immuno-
blotted for RB using an antibody that
detects both the hypo- and hyperphospho-
rylated forms of RB (851) and also a
phospho-specific RB (ppRB) antibody
(Ser-780).
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that the ability of BRG-1 to cooperate with RB for cell cycle
arrest is dependent on its ability to facilitate RB-mediated
inhibition of cyclin A protein. Therefore, to confirm that Brm
can functionally substitute for BRG-1 in regard to mediating
RB inhibitory signals to its critical effector cyclin A, PSM-RB
was co-transfected with Brm in A427 and C33A cells. Ectopic
expression of vector, Brm, or PSM-RB alone did not alter en-
dogenous cyclin A levels in either A427 or C33A cells (Fig. 5B,
lanes 1–3, left and right panels). However, co-expression of Brm
with PSM-RB restored RB signaling to cyclin A, as evidenced
by a significant decrease in cyclin A protein (Fig. 5B, lane 4, left
and right panels). Thus, Brm can substitute for BRG-1 in
restoring RB-mediated signaling to cyclin A to inhibit cell cycle
progression.
Because reintroduction of either BRG-1 or Brm into C33A
and A427 cells restored RB inhibitory action, we investigated
whether this was sufficient to restore CD44 signaling. To test
this, SW13, A427, and C33A cells were co-transfected with
either vector, BRG-1, or Brm along with a puromycin resist-
ance plasmid. As expected, expression of vector had no effect on
CD44 protein. However, co-expression of BRG-1 or Brm in
SW13, A427, or C33A cells restored CD44 expression to similar
levels, providing additional evidence that Brm can functionally
substitute for BRG-1 (Fig. 5C, lanes 1–3, left, middle, and right
panels).
BRG-1/Brm Mediates the RB-dependent CDDP Checkpoint
in A427 Cells—The chemotherapeutic agent CDDP is com-
monly prescribed for the treatment of multiple tumor types
(47). CDDP treatment is known to generate inter- and intra-
molecular DNA cross-links. This damage elicits an RB-depend-
ent cell cycle arrest in mouse embryonic fibroblasts as well as
a host of tumor lines (37, 38). To examine whether loss of
BRG-1 or Brm can mediate resistance to CDDP, SW13 cells
were treated with 32 M CDDP, a dose previously described to
cause a RB-dependent cell cycle arrest (37). Treatment of the
RB-sensitive TSU-Pr1 cell line and the RB-resistant SW13 cell
line with CDDP resulted in efficient dephosphorylation of RB
(Fig. 6A, lanes 2 and 4). Next, we monitored signaling to critical
cell cycle targets and determined that treatment of TSU-Pr1
with CDDP resulted in the attenuation of cyclin A protein
expression by 74.2% when compared with untreated cells.
However, cyclin E and Cdk2 levels were not significantly al-
tered by CDDP treatment, after comparison to untreated cells
and normalization to -tubulin (Fig. 6B, lanes 1 and 2). Also,
treatment of TSU-Pr1 did not alter p53 levels, supporting the
observation that p53 is functionally inactivated in this cell line.
Analyses of SW13 cells treated with and without CDDP re-
vealed no alteration in cyclin A, cyclin E, or Cdk2 protein
expression after normalization to -tubulin (Fig. 6B, lanes 3
versus 4). In addition, CDDP signaling to p53 was also compro-
mised in SW13 cells. These data suggest that although RB is
dephosphorylated in response to CDDP in SW13 cells, RB
activity is compromised.
To confirm this hypothesis, we evaluated the effect of CDDP
on cell cycle progression. We observed that treatment of TSU-
Pr1 with CDDP resulted in the significant inhibition of BrdUrd
incorporation when compared with untreated cells (Fig. 6C, left
panel). This finding is consistent with CDDP activating RB,
FIG. 3. A427 cells are resistant to active RB. HCT-116, Hs 700t,
and Hs 683 cells were co-transfected with an H2B-GFP expression
plasmid (0.125 g) and vector (3.875 g) or PSM-RB (3.875 g) using
calcium phosphate. A427 and WiDr cells were co-transfected with an
H2B-GFP expression plasmid (0.062 g) and vector (1.94 g) or
PSM-RB (1.94 g) using the FuGENE transfection reagent. The per-
centage of BrdUrd-positive cells was determined from at least two
independent experiments with at least 150 transfected cells (GFP-
positive) scored per experiment.
FIG. 4. Loss of BRG-1 and Brm correlates with RB resistance.
Thirty micrograms of lysate was isolated from subconfluent HeLa,
SW13, C33A, SU86.86, HCT-116, Hs 700t, Hs 683, TSU-Pr1, SNU-C2B,
WiDr, A427, NCI-H1299, and Hs 578t cells using an 8 M urea extraction
(8 M urea, 0.1 M NaH2PO4, 10 mM Tris, pH 8). The lysates were then
separated via SDS-PAGE and blotted for BRG-1, Brm, Baf 250, Baf 180,
Baf 155, Baf 53, and Baf 47 in A and CD44 in B.
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resulting in the down-regulation of cyclin A (Fig. 6B, lane 2).
Strikingly, treatment of the SW13 cell line with CDDP had no
effect on the ability of these cells to undergo DNA synthesis
when compared with the untreated SW13 cells (Fig. 6C, right
panel). To determine whether loss of BRG-1 and Brm confers a
defect in the CDDP checkpoint in SW13 cells, either BRG-1 or
Brm was co-transfected with H2B-GFP, and the transfected
SW13 cells were monitored for their ability to incorporate
BrdUrd in the presence and absence of CDDP. Interestingly,
reintroduction of either BRG-1 or Brm into SW13 cells restored
the ability of CDDP to cause a G1 arrest, as evidenced by a
respective 85 and 73.4% decrease in BrdUrd incorporation
when compared with vector-treated cells (Fig. 6D). Therefore,
reintroduction of either BRG-1 or Brm restores the RB-depend-
ent CDDP checkpoint in SW13 cells.
DISCUSSION
The SWISNF complex mediates both transcriptional activa-
tion as well as repression (11). Specifically, it has been shown
that both BRG-1 and Brm subunits use the energy of ATP to
remodel chromatin structure as well as facilitate the transfer of
nucleosomes from one DNA template to another in vitro (4, 5).
The BRG-1 and Brm subunits of the SWISNF complex share
75% homology at the amino acid level; however, whether these
two subunits carry out similar functions in a promoter or cell
type-specific fashion remains equivocal (11). Because BRG-1 is
involved in regulating cellular proliferation through its ability
to cooperate with RB, the finding that it is lost or mutated in
human tumors suggested a role in tumor suppression (19).
Therefore, we hypothesized that loss or mutation of BRG-1 in
the discrete tumor cell lines compromise RB inhibitory action.
FIG. 5. Reintroduction of core SWISNF subunits restores RB inhibitory signals. A, A427 cells (left panel) were co-transfected with an
H2B-GFP-expression plasmid (0.062 g) and either vector (1.94 g), PSM-RB (1.94 g), BRG-1 (1.94 g), Brm (1.94 g), BRG-1 (1.0 g)  PSM-RB
(1.0 g), or Brm (1.0 g)  PSM-RB (1.0 g) using the FuGENE transfection reagent. In addition, C33A cells (right panel) were co-transfected with
an H2B-GFP expression plasmid (0.125 g) and either vector (3.875 g), PSM-RB (3.875 g), BRG-1 (3.875 g), Brm (3.875 g), BRG-1 (1.9 g)
 PSM-RB (1.90 g), or Brm (1.9 g)  PSM-RB (1.9 g) using calcium phosphate. The percentage of BrdUrd-positive cells was determined from
at least two independent experiments with at least 150 transfected (GFP-positive) scored per experiment. B, using the aforementioned transfection
methods, A427 cells (left panel) were co-transfected with 0.5 g of pBabe-Puro and either 7.5 g of vector (lane 1), 7.5 g of PSM-RB (lane 2), 7.5
g of Brm (lane 3), and 3.75 g of Brm  3.75 g of PSM-RB (lane 4). In addition, C33A cells (right panel) were co-transfected with 1 g of
pBabe-Puro and either 15 g of vector (lane 1), 15 g of PSM-RB (lane 2), 15 g of Brm (lane 3), and 7.5 g of Brm  7.5 g of PSM-RB (lane 4)
as indicated. After puromycin selection, equal total protein was resolved by SDS-PAGE and then immunoblotted for cyclin A and Cdk4. C, SW13
cells (left panel) were co-transfected with 1 g of pBabe-Puro and either 15 g of vector (lane 1), 15 g of BRG-1 (lane 2), or 15 g of Brm (lane
3). A427 cells (middle panel) were co-transfected with 0.5 g of pBabe-Puro and either 7.5 g of vector (lane 1), 7.5 g of BRG-1 (lane 2), or 7.5
g of Brm (lane 3). C33A cells (right panel) were co-transfected with 1 g of pBabe-Puro and either 15 g of vector (lane 1), 15 g of Brm (lane
2) or 15 g of BRG-1 (lane 3). After puromycin selection, equal total protein was resolved by SDS-PAGE and then immunoblotted for CD44 and
Cdk4.
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Through our analysis, we demonstrate that the majority of
BRG-1 mutant tumor lines were sensitive to the RB pathway.
However, we identified the A427 lung carcinoma cell line to be
resistant to both the inhibitory action of p16ink4a, which acti-
vates endogenous RB, and PSM-RB. To investigate how these
cells bypass RB signaling, we analyzed the status of BRG-1 and
Brm as well as the other Baf subunits in these tumor lines. Our
findings revealed that A427, like the previously characterized
RB-resistant C33A and SW13 cell lines, were compromised for
both BRG-1 and Brm expression. In addition, CD44, an RB-
independent marker for BRG-1 activity, was also absent in
A427, similar to C33A and SW13 cells. Reintroduction of either
BRG-1 or Brm restored both RB inhibitory action and CD44
expression in the resistant SW13, A427, and C33A cells. Using
the commonly prescribed chemotherapeutic agent cisplatin,
which has been shown to cause a physiological stress to acti-
vate RB, we demonstrate that SW13 cells are compromised in
their response to CDDP (37, 38, 47, 48). Furthermore, ectopic
expression of BRG-1 or Brm alone in SW13 restored their
sensitivity to activation of the RB pathway by CDDP. Thus,
these studies demonstrate that Brm can compensate for BRG-1
in mediating RB inhibitory signals.
RB is lost or functionally inactivated in the majority of hu-
man tumors (22, 23, 27, 28). The tumor suppressor activity of
RB is manifested through its ability to inhibit cell cycle pro-
gression. This inhibitory action of RB requires the recruitment
of accessory proteins to generate an RB-dependent transcrip-
tional repressor complex (22–24, 26–28, 31). One critical com-
ponent of the RB repressor complex is the SWISNF subunit
BRG-1 (17, 18, 20, 30). In this study we show that in the Hs
700t, TSU-PR1, and NCI-H1299 tumor cell lines, Brm is pres-
ent, but BRG-1 expression is attenuated. Interestingly, these
cell lines are sensitive to RB, suggesting that Brm may com-
pensate for the lack of BRG-1 expression in the context of these
signaling pathways. This hypothesis was confirmed after res-
toration of Brm restored RB-mediated transcriptional repres-
sion to cause cell cycle arrest. Interestingly, not only RB, but
the expression of CD44 appears to adhere to the presence of
BRG-1 and Brm.
The mechanism through which BRG-1 and Brm expression is
attenuated in the different tumor lines is currently unclear.
Presumably germ line mutations in BRG-1 alter its stability/
expression. Surprisingly, no mutations have been identified in
SW13 cells despite low levels of BRG-1/Brm mRNA.2 To date,
no germ line mutations of Brm have been described. However,
it has been shown that ectopic expression of Ras in 3T3 cells
results in the specific attenuation Brm message, suggesting
that alternative mechanisms exist for reducing Brm mRNA
levels (49). Therefore, different tumor lines may utilize dispar-
ate genetic mechanisms for attenuating BRG-1 and Brm ex-
pression. Other gene products have been previously shown to
be altered by epigenetic pathways in tumor cells. Specifically,
the tumor suppressors p16ink4a and p53 as well as RB are
inactivated in cancer via methylation of their promoter (50–
52). Therefore, BRG-1 or Brm loss might be caused through
similar epigenetic pathways. Because we observed reduced
BRG-1 protein expression and not Brm in the Hs 700t, TSU-
PR1, and NCI-H1299 cell lines, this finding suggests that mul-
tiple hits may occur in these tumor lines that result in the
attenuation of BRG-1. The biological significance of selectively
targeting BRG-1 or Brm is still unclear, although knockout
studies have revealed distinct roles for these subunits. Specif-
ically, mice homozygous for BRG-1 die during the periimplan-
tation stage, whereas Brm / mice develop normally (53, 54).
Whether the disparate phenotypes observed is reflective of
developmental timing remains to be determined.
2 M. W. Strobeck, D. N. Reisman, R. W. Gunawardena, B. L. Betz,
S. P. Angus, K. E. Knudsen, T. F. Kowalik, B. E. Weissman, and E. S.
Knudsen, unpublished information.
FIG. 6. Loss of BRG-1 mediates CDDP resistance. A, TSU-Pr1
and SW13 cells were treated with or without 32 M CDDP and then
harvested for immunoblot analysis. Next, equal total protein was re-
solved by SDS-PAGE and then immunoblotted for RB. B, in addition,
after TSU-Pr1 and SW13 cells were treated with or without CDDP, we
immunoblotted for cyclin A, cyclin E, Cdk2, -tubulin, and p53. The
level of cyclin A protein was normalized to that of -tubulin. C, TSUPr1
(left panel) and SW13 cells (right panel) were seeded onto coverslips,
treated with and without CDDP, and monitored for BrdUrd incorpora-
tion. D, SW13 cells were co-transfected with an H2B-GFP expression
plasmid (0.125 g) and either vector (3.875 g), BRG-1 (3.875 g), or
Brm (3.875 g). After the cells were transfected, they were treated
either with 0 or 32 M CDDP for 24 h. The percentage of BrdUrd-
positive cells was determined from at least two independent experi-
ments with at least 150 transfected (GFP-positive) scored per
experiment.
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SWISNF subunits have been reported to be targeted in
cancer (55). Specifically, it was shown that the SWISNF sub-
unit hSNF5/Ini1 is lost in rhabdomyosarcoma, a rare pediatric
cancer (56, 57). Loss of this subunit is thought to contribute to
tumorigenesis because mice heterozygous for hSNF5/Ini1 de-
velop malignant rhabdoid tumors (58–60). Interestingly,
BRG-1 is lost in 10% of tumor lines, and mice heterozygous
for BRG-1 develop tumors of apocrine origin (54). In this study,
loss of some of the other SWISNF subunits were observed in
the discrete tumor lines, providing additional evidence that
alternative accessory subunits are lost. Specifically, C33A was
compromised for Baf 250, whereas SW13 lost Baf 180 (61).
However, these accessory Baf subunits do not appear to be
required for cooperating with RB or signaling to CD44, because
reintroduction of either BRG-1 or Brm alone was sufficient to
restore these discrete events.
The RB pathway is compromised in a large number of human
tumors. Here, we show that dual loss of BRG-1 and Brm is
tantamount to RB loss. In addition, loss of both of these central
subunits renders cells resistant to activation of the RB path-
way by CDDP. Thus, these results provide evidence that Brm
can compensate for BRG-1 in cooperating with RB.
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